Astrazeneca Pharma India Ltd vs Strides Pharma Science Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 11, 2026

Key Highlights

The Latest Trading Price of Astrazeneca Pharma India Ltd is ₹ 8538 as of 11 May 15:30 . The P/E Ratio of Astrazeneca Pharma India Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Strides Pharma Science Ltd changed from 28.2 on March 2021 to 1.7 on March 2025 . This represents a CAGR of -42.98% over 5 years The Market Cap of Astrazeneca Pharma India Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Strides Pharma Science Ltd changed from ₹ 7573 crore on March 2021 to ₹ 6165 crore on March 2025 . This represents a CAGR of -4.03% over 5 years The revenue of Astrazeneca Pharma India Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Strides Pharma Science Ltd for the Dec '25 is ₹ 1301 crore as compare to the Sep '25 revenue of ₹ 1247 crore. This represent the growth of 4.29% The ebitda of Astrazeneca Pharma India Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Strides Pharma Science Ltd for the Dec '25 is ₹ 339.48 crore as compare to the Sep '25 ebitda of ₹ 248.89 crore. This represent the growth of 36.4% The net profit of Astrazeneca Pharma India Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of Strides Pharma Science Ltd changed from ₹ 3349 crore to ₹ 208.12 crore over 7 quarters. This represents a CAGR of -79.56% The Dividend Payout of Astrazeneca Pharma India Ltd changed from 5.36 % on March 2021 to 69.12 % on March 2025 . This represents a CAGR of 66.76% over 5 yearsThe Dividend Payout of Strides Pharma Science Ltd changed from 28.66 % on March 2021 to 1.28 % on March 2025 . This represents a CAGR of -46.30% over 5 years .

About Astrazeneca Pharma India Ltd

AstraZeneca Pharma India Limited (APIL) was incorporated on July 11, 1979.
The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and co-ordinates clinical trial services with an overseas group company.
The major therapy areas where the company operates are Onocology, Alimentary & Metabolism, Cardio Vascular, Renal, Diabetes, Respiratory and Oncology. AstraZeneca Pharma India, formerly known as Astra-IDL (AIL), was an erstwhile joint venture of Astra Zeneca, UK and Hinduja controlled IDL. Astra Pharmaceuticals AB, Sweden acquired all of the 1287500 equity shares in the Company of IDL, representing 25.75% of the Company's issued and paid up equity share capital.
Consequently, the Company became a subsidiary of Astra, which is a direct wholly owned subsidiary of Astra AB, Sweden (now known as AstraZeneca Pharmaceuticals AB Sweden) and an indirect wholly owned subsidiary of AstraZeneca Plc, the Group parent Company.

About Strides Pharma Science Ltd

Strides Pharma Science Limited was originally incorporated under the name 'Strides Arcolab Limited ' on June 28, 1990.
In FY 2016, Shasun Pharmaceuticals Limited merged with Strides Arcolab Limited forming a new identity 'Strides Shasun Limited', making it effective from 19 November, 2015 and name of the Company was changed to 'Strides Pharma Science Limited' from 'Strides Shasun Limited' effective on July 18, 2018. Strides Pharma Science is a global pharmaceutical company headquartered in Bengaluru, India.
The Company is an integrated manufacturer and exporter of Finished Pharmaceutical Dosage forms for both branded and generic.
It manufactures a very wide spectrum of ethical pharmaceutical products, OTC products and nutraceuticals.
Their dosage forms range includes tablets, capsules, soft gelatin capsules, parenterals and semisolids.

FAQs for the comparison of Astrazeneca Pharma India Ltd and Strides Pharma Science Ltd

Which company has a larger market capitalization, Astrazeneca Pharma India Ltd or Strides Pharma Science Ltd?

Market cap of Astrazeneca Pharma India Ltd is 21,347 Cr while Market cap of Strides Pharma Science Ltd is 10,654 Cr

What are the key factors driving the stock performance of Astrazeneca Pharma India Ltd and Strides Pharma Science Ltd?

The stock performance of Astrazeneca Pharma India Ltd and Strides Pharma Science Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Astrazeneca Pharma India Ltd and Strides Pharma Science Ltd?

As of May 11, 2026, the Astrazeneca Pharma India Ltd stock price is INR ₹8538.85. On the other hand, Strides Pharma Science Ltd stock price is INR ₹1155.9.

How do dividend payouts of Astrazeneca Pharma India Ltd and Strides Pharma Science Ltd compare?

To compare the dividend payouts of Astrazeneca Pharma India Ltd and Strides Pharma Science Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.